

# Product data sheet



MedKoo Cat#: 319826 Name: Evatanepag CAS#: 223488-57-1 (free acid) Chemical Formula: C <sub>25</sub> H <sub>28</sub> N <sub>2</sub> O <sub>5</sub> S Exact Mass: 468.1719 Molecular Weight: 468.568	
Product supplied as: Powder	
Purity (by HPLC): ≥ 98%	
Shipping conditions: Ambient temperature	
Storage conditions: Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.	

## 1. Product description:

Evatanepag, also known as CP-533536, is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing.

## 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

## 3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	32.0	68.29

## 4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.13 mL	10.67 mL	21.34 mL
5 mM	0.43 mL	2.13 mL	4.27 mL
10 mM	0.21 mL	1.07 mL	2.13 mL
50 mM	0.04 mL	0.21 mL	0.43 mL

## 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

## 6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

TBD

In vivo study

1. Kurihara R, Imazumi K, Takamatsu H, Ishizu K, Yoshino T, Masuda N. Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction. *Low Urin Tract Symptoms*. 2016 May;8(2):130-5. doi: 10.1111/luts.12080. Epub 2014 Nov 6. PMID: 27111626.

2. Cameron KO, Lefker BA, Ke HZ, Li M, Zawistoski MP, Tjoa CM, Wright AS, DeNinno SL, Paralkar VM, Owen TA, Yu L, Thompson DD. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. *Bioorg Med Chem Lett*. 2009 Apr 1;19(7):2075-8. doi: 10.1016/j.bmcl.2009.01.059. Epub 2009 Jan 23. PMID: 19250823.

## 7. Bioactivity

Biological target:

Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.

In vitro activity

# Product data sheet



TBD

## In vivo activity

---

CP-533,536 dose-dependently decreased UPP elevated by midodrine in anesthetized rats. In contrast, CP-533,536 did not affect maximum voiding pressure, intercontraction interval, or intravesical threshold pressure. In conscious rats, midodrine (1 mg/kg, i.v.) markedly increased RV and reduced VE. CP-533,536 dose-dependently ameliorated increases in RV and decreases in VE induced by midodrine.

Reference: Low Urin Tract Symptoms. 2016 May;8(2):130-5. <https://pubmed.ncbi.nlm.nih.gov/27111626/>

*Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.*